♥

Torrent Pharmaceuticals Limited

ISIN : INE685A01028
NSE : TORNTPHARM
BSE : 500420
Face Value : 5
Industry : Pharmaceuticals & Drugs

EPS : 48.94
EPS (TTM) : 53.25
Price to Earning (P/E) : 65.96
Book Value : 202.57
Price to Bookvalue (P/B) : 15.93
Dividend Yield : 1 %
Return on Equity (ROE) : 25.38 %
Return on Capital Employed (ROCE) : 24.28 %

Torrent Pharmaceuticals share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	4099.05 - 3989.1 -2.7 %
Low / High	3871.25 - 4099.05 5.9 %
Trade Volume	13,521
52 Week Low / High	3101 - 4479.7 44.5 %

YOU MAY ALSO LIKE

Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
Stock market course tutorial
Stock Market Investment Course explained in simple words.
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR TORRENT PHARMACEUTICALS LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	23470	22910	24910	24910	25910	26600	27320	27450	28590	28890
Total Income	23770	23070	24810	25000	26250	26860	26990	27760	28830	28730
Total Expenditure	16350	16120	17670	17640	18000	18350	18630	18620	19550	19500
Other Income	300	160	-100	90	340	260	-330	310	240	-160
Operating Profit	7420	6950	7140	7360	8250	8510	8360	9140	9280	9230
Interest	550	690	1020	1070	1030	910	800	800	750	640
Exceptional Items							880
PBDT	6870	6260	6120	6290	7220	7600	8440	8340	8530	8590
Depreciation	1550	1630	1930	1960	1910	2010	2130	2030	1970	1980
Profit Before Tax	5320	4630	4190	4330	5310	5590	6310	6310	6560	6610
Tax	1780	1510	1360	1460	1530	1730	1880	1820	1990	2080
Profit After Tax	3540	3120	2830	2870	3780	3860	4430	4490	4570	4530
Net Profit	3540	3120	2830	2870	3780	3860	4430	4490	4570	4530
Equity Capital	846.2	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3
Face Value (IN RS)	5	5	5	5	5	5	5	5	5	5
Reserves	61420	59220	61640
Calculated EPS	20.92	9.22	8.36	8.48	11.17	11.4	13.09	13.27	13.5	13.38
Diluted Eps After Extraordinary Items	20.9	9.22	8.36	8.48	11.18	11.39	13.1	13.27	13.51	13.37
Diluted Eps Before Extraordinary Items	20.9	9.22	8.36	8.48	11.18	11.39	13.1	13.27	13.51	13.37

STANDALONE QUARTERLY RESULT FOR TORRENT PHARMACEUTICALS LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	19330	19280	18570	19200	21210	21460	21230	21430	24380	24340
Total Income	19620	19390	18720	19460	21320	21610	21120	22190	24590	24270
Total Expenditure	12680	13080	12720	13420	13840	14100	14220	14270	15390	15130
Other Income	290	110	150	260	110	150	-110	760	210	-70
Operating Profit	6940	6310	6000	6040	7480	7510	6900	7920	9200	9140
Interest	510	620	910	940	900	770	690	670	640	540
PBDT	6430	5690	5090	5100	6580	6740	6210	7250	8560	8600
Depreciation	1490	1560	1560	1820	1830	1920	1910	1950	1890	1900
Profit Before Tax	4940	4130	3530	3280	4750	4820	4300	5300	6670	6700
Tax	1670	1410	1240	1090	1520	1550	1330	1200	1980	2100
Profit After Tax	3270	2720	2290	2190	3230	3270	2970	4100	4690	4600
Net Profit	3270	2720	2290	2190	3230	3270	2970	4100	4690	4600
Equity Capital	846.2	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3	1692.3
Face Value (IN RS)	5	5	5	5	5	5	5	5	5	5
Reserves	65400	63080	65160
Calculated EPS	19.32	8.04	6.77	6.47	9.54	9.66	8.78	12.11	13.86	13.59
Diluted Eps After Extraordinary Items	19.35	8.02	6.78	6.46	9.55	9.65	8.78	12.12	13.86	13.6
Diluted Eps Before Extraordinary Items	19.35	8.02	6.78	6.46	9.55	9.65	8.78	12.12	13.86	13.6

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR TORRENT PHARMACEUTICALS LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	85080	96200	107280
Total Income	87050	96650	107860
Total Expenditure	60770	67780	73600
Other Income	1970	450	580
Operating Profit	26280	28870	34260
Interest	2550	3330	3540
Exceptional Items	-4850		880
PBDT	18880	25540	31600
Depreciation	6620	7070	8080
Profit Before Tax	12260	18470	23520
Tax	4490	6020	6960
Profit After Tax	7770	12450	16560
Net Profit	7770	12450	16560
Equity Capital	846.2	1692.3	1692.3
Face Value (IN RS)	5	5	5
Reserves	58680	60290	66870
Calculated EPS	45.91	36.78	48.93
Diluted Eps After Extraordinary Items	45.93	36.79	48.94
Diluted Eps Before Extraordinary Items	45.93	36.79	48.94

STANDALONE ANNUAL RESULT FOR TORRENT PHARMACEUTICALS LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	67420	76950	85330
Total Income	69460	77770	86240
Total Expenditure	46420	52300	56430
Other Income	2040	820	910
Operating Profit	23040	25470	29810
Interest	2360	2980	3030
PBDT	20680	22490	26780
Depreciation	6020	6720	7610
Profit Before Tax	14660	15770	19170
Tax	4750	5250	5600
Profit After Tax	9910	10520	13570
Net Profit	9910	10520	13570
Equity Capital	846.2	1692.3	1692.3
Face Value (IN RS)	5	5	5
Reserves	62610	62870	66600
Calculated EPS	58.56	31.08	40.09
Diluted Eps After Extraordinary Items	58.59	31.07	40.1
Diluted Eps Before Extraordinary Items	58.59	31.07	40.1

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	14878.6 Cr	15211.1 Cr	16352.5 Cr	16705.4 Cr
Sales	14760 Cr	15121.9 Cr	16196 Cr	16539.9 Cr
Net Sales	8004.83 Cr	8508.04 Cr	9620.15 Cr	10727.8 Cr
Increase/Decrease in Stock	-279.24 Cr	73.86 Cr	166.19 Cr	-155.01 Cr
Raw Material Consumed	2239.36 Cr	2156.89 Cr	2347.01 Cr	2613.96 Cr
Opening Raw Materials	741.23 Cr	985.23 Cr	841.24 Cr	752.49 Cr
Purchases Raw Materials	1478.39 Cr	1182.25 Cr	1169.68 Cr	1320.96 Cr
Closing Raw Materials	985.23 Cr	841.24 Cr	752.49 Cr	643.12 Cr
Other Direct Purchases / Brought in cost	1004.97 Cr	830.65 Cr	1088.58 Cr	1183.63 Cr
Power & Fuel Cost	122.94 Cr	144.19 Cr	155.28 Cr	145.2 Cr
Electricity & Power	122.94 Cr	144.19 Cr	155.28 Cr	145.2 Cr
Employee Cost	1439.62 Cr	1526.45 Cr	1677.69 Cr	1984.4 Cr
Salaries, Wages & Bonus	1245.47 Cr	1304.67 Cr	1432.61 Cr	1695.22 Cr
Contributions to EPF & Pension Funds	118.24 Cr	133.69 Cr	153.11 Cr	178.4 Cr
Workmen and Staff Welfare Expenses	49.45 Cr	60.39 Cr	62.97 Cr	76.91 Cr
Other Manufacturing Expenses	550.92 Cr	591.13 Cr	570.79 Cr	570.58 Cr
Processing Charges	74.8 Cr	88.36 Cr	83.99 Cr	95.5 Cr
Packing Material Consumed	186.3 Cr	211.26 Cr	221.99 Cr	227.26 Cr
General and Administration Expenses	647.22 Cr	637.65 Cr	775.3 Cr	980.72 Cr
Professional and legal fees	139.89 Cr	110.71 Cr	137.2 Cr	185.08 Cr
Traveling and conveyance	61.68 Cr	81.64 Cr	158.14 Cr	205.59 Cr
Selling and Distribution Expenses	742.63 Cr	884.91 Cr	1026.99 Cr	1129.68 Cr
Miscellaneous Expenses	74.78 Cr	61.69 Cr	76.93 Cr	94.72 Cr
Provision for doubtful debts	0	90 Lk	2.27 Cr	7.08 Cr
Loss on disposal of fixed assets(net)	0	0	0	2 Lk
Loss on foreign exchange fluctuations	0	0	18.08 Cr	3.91 Cr
Total Expenditure	5538.23 Cr	6076.77 Cr	6796.18 Cr	7364.25 Cr
Other Income	75.73 Cr	196.56 Cr	63.22 Cr	61.97 Cr
Interest Received	5.07 Cr	7.15 Cr	14.78 Cr	11.48 Cr
Profit on sale of Fixed Assets	0	0	21.62 Cr	0
Profits on sale of Investments	15.58 Cr	9.88 Cr	19.37 Cr	18.12 Cr
Foreign Exchange Gains	31.97 Cr	169.54 Cr	0	0
Operating Profit	2542.33 Cr	2627.83 Cr	2887.19 Cr	3425.56 Cr
Interest	358.28 Cr	255.06 Cr	333.44 Cr	353.56 Cr
Bank Charges etc	2.12 Cr	2.13 Cr	1.2 Cr	93 Lk
PBDT	2184.05 Cr	2372.77 Cr	2553.75 Cr	3072 Cr
Depreciation	657.79 Cr	662.16 Cr	706.59 Cr	808.27 Cr
Profit Before Taxation & Exceptional Items	1526.26 Cr	1710.61 Cr	1847.16 Cr	2263.73 Cr
Exceptional Income / Expenses	0	-484.7 Cr	0	88.38 Cr
Profit Before Tax	1526.26 Cr	1225.91 Cr	1847.16 Cr	2352.11 Cr
Provision for Tax	274.38 Cr	448.73 Cr	601.93 Cr	695.73 Cr
Current Income Tax	334.08 Cr	346.22 Cr	354.77 Cr	470.28 Cr
Deferred Tax	-52.98 Cr	106.53 Cr	227.62 Cr	220.47 Cr
Profit After Tax	1251.88 Cr	777.18 Cr	1245.23 Cr	1656.38 Cr
Consolidated Net Profit	1251.88 Cr	777.18 Cr	1245.23 Cr	1656.38 Cr
Profit Balance B/F	1893.03 Cr	2806.47 Cr	2916.68 Cr	3303.19 Cr
Appropriations	3144.91 Cr	3583.65 Cr	4161.91 Cr	4959.57 Cr
Other Appropriation	44 Lk	243.87 Cr	384.72 Cr	272.59 Cr
Equity Dividend %	700	960	440	560
Earnings Per Share	73.97	45.92	36.79	48.94
Adjusted EPS	73.97	45.92	36.79	48.94

STANDALONE PROFIT / LOSS FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	6551.73 Cr	6864.11 Cr	7845.31 Cr	8707.95 Cr
Sales	6433.94 Cr	6787.75 Cr	7696.87 Cr	8544.64 Cr
Net Sales	6450.83 Cr	6742.32 Cr	7695.2 Cr	8532.9 Cr
Increase/Decrease in Stock	-150.14 Cr	-18.34 Cr	128.44 Cr	-68.61 Cr
Raw Material Consumed	1633.51 Cr	1715.7 Cr	1789.03 Cr	1973.13 Cr
Opening Raw Materials	730.52 Cr	976.32 Cr	839.77 Cr	751.07 Cr
Purchases Raw Materials	1480.32 Cr	1181.91 Cr	1166.77 Cr	1315.61 Cr
Closing Raw Materials	976.32 Cr	839.77 Cr	751.07 Cr	642.03 Cr
Other Direct Purchases / Brought in cost	398.99 Cr	397.24 Cr	533.56 Cr	548.48 Cr
Power & Fuel Cost	122.04 Cr	140 Cr	153.21 Cr	143.43 Cr
Electricity & Power	122.04 Cr	140 Cr	153.21 Cr	143.43 Cr
Employee Cost	1097.12 Cr	1097.93 Cr	1251.22 Cr	1450.67 Cr
Salaries, Wages & Bonus	969.94 Cr	960.23 Cr	1101.41 Cr	1277.74 Cr
Contributions to EPF & Pension Funds	71.58 Cr	76.75 Cr	85.42 Cr	97.26 Cr
Workmen and Staff Welfare Expenses	32.81 Cr	37.97 Cr	40.02 Cr	48.35 Cr
Other Manufacturing Expenses	467.64 Cr	525.94 Cr	518.96 Cr	534.71 Cr
Processing Charges	47.31 Cr	47.42 Cr	50.9 Cr	72.3 Cr
Packing Material Consumed	186.3 Cr	210.14 Cr	221.95 Cr	227.26 Cr
General and Administration Expenses	427.08 Cr	445.93 Cr	543.33 Cr	636.24 Cr
Professional and legal fees	55.73 Cr	48.68 Cr	75.08 Cr	79.61 Cr
Traveling and conveyance	47.05 Cr	55.74 Cr	116.25 Cr	150.12 Cr
Selling and Distribution Expenses	595.84 Cr	673.65 Cr	788.92 Cr	886.54 Cr
Miscellaneous Expenses	60.41 Cr	60.75 Cr	56.93 Cr	87.62 Cr
Provision for doubtful debts	8 Lk	-4 Lk	35 Lk	3.92 Cr
Total Expenditure	4253.5 Cr	4641.56 Cr	5230.04 Cr	5643.73 Cr
Other Income	118.08 Cr	204.17 Cr	81.88 Cr	91.49 Cr
Interest Received	4.15 Cr	3.26 Cr	11.15 Cr	2.54 Cr
Dividend Received	48.38 Cr	0	0	50.2 Cr
Profit on sale of Fixed Assets	0	0	22.45 Cr	3.03 Cr
Profits on sale of Investments	15.58 Cr	10.14 Cr	19.51 Cr	18.12 Cr
Foreign Exchange Gains	37.03 Cr	173.38 Cr	10.36 Cr	4.18 Cr
Operating Profit	2315.41 Cr	2304.93 Cr	2547.04 Cr	2980.66 Cr
Interest	339.46 Cr	236.29 Cr	297.68 Cr	303.04 Cr
Bank Charges etc	2.12 Cr	2.13 Cr	1.2 Cr	93 Lk
PBDT	1975.95 Cr	2068.64 Cr	2249.36 Cr	2677.62 Cr
Depreciation	609.84 Cr	602.43 Cr	672.34 Cr	761.05 Cr
Profit Before Taxation & Exceptional Items	1366.11 Cr	1466.21 Cr	1577.02 Cr	1916.57 Cr
Profit Before Tax	1366.11 Cr	1466.21 Cr	1577.02 Cr	1916.57 Cr
Provision for Tax	228.26 Cr	474.76 Cr	525.63 Cr	559.49 Cr
Current Income Tax	247.77 Cr	253.27 Cr	274.2 Cr	335.2 Cr
Deferred Tax	-19.51 Cr	221.49 Cr	251.43 Cr	224.29 Cr
Profit After Tax	1137.85 Cr	991.45 Cr	1051.39 Cr	1357.08 Cr
Consolidated Net Profit	1137.85 Cr	991.45 Cr	1051.39 Cr	1357.08 Cr
Profit Balance B/F	2093.3 Cr	2899.91 Cr	3212.92 Cr	3394.21 Cr
Appropriations	3231.15 Cr	3891.36 Cr	4264.31 Cr	4751.29 Cr
Other Appropriation	-6.76 Cr	255.34 Cr	396.1 Cr	270.32 Cr
Equity Dividend %	700	960	440	560
Earnings Per Share	67.23	58.58	31.06	40.1
Adjusted EPS	67.23	58.58	31.06	40.1

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR TORRENT PHARMACEUTICALS LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	1526.26 Cr	1225.91 Cr	1847.16 Cr	2352.11 Cr
Adjustment	998.18 Cr	1349.95 Cr	937.24 Cr	993.99 Cr
Changes In working Capital	-338.25 Cr	-351.85 Cr	-18.2 Cr	418.08 Cr
Cash Flow after changes in Working Capital	2186.19 Cr	2224.01 Cr	2766.2 Cr	3764.18 Cr
Cash Flow from Operating Activities	2010.69 Cr	1802.99 Cr	2368.13 Cr	3266.08 Cr
Cash Flow from Investing Activities	-449.42 Cr	-196.63 Cr	-2415.31 Cr	-167.9 Cr
Cash Flow from Financing Activitie	-1656.13 Cr	-1781.05 Cr	77.36 Cr	-2779.64 Cr
Net Cash Inflow / Outflow	-94.86 Cr	-174.69 Cr	30.18 Cr	318.54 Cr
Opening Cash & Cash Equivalents	661.82 Cr	572.56 Cr	398.4 Cr	508.53 Cr
Cash & Cash Equivalent on Amalgamation / Take over / Merger	0	0	58.83 Cr	0
Effect of Foreign Exchange Fluctuations	5.6 Cr	53 Lk	21.12 Cr	8.07 Cr
Closing Cash & Cash Equivalent	572.56 Cr	398.4 Cr	508.53 Cr	835.14 Cr

STANDALONE CASH FLOW FOR TORRENT PHARMACEUTICALS LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	1366.11 Cr	1466.21 Cr	1577.02 Cr	1916.57 Cr
Adjustment	890.14 Cr	827.91 Cr	990.49 Cr	957.61 Cr
Changes In working Capital	-468.12 Cr	86.25 Cr	-29.64 Cr	343.6 Cr
Cash Flow after changes in Working Capital	1788.13 Cr	2380.37 Cr	2537.87 Cr	3217.78 Cr
Cash Flow from Operating Activities	1578.23 Cr	2140.1 Cr	2265.41 Cr	2893.1 Cr
Cash Flow from Investing Activities	-316.28 Cr	-159.7 Cr	-2384.07 Cr	-296.07 Cr
Cash Flow from Financing Activitie	-1586.54 Cr	-1977.27 Cr	80.74 Cr	-2577.57 Cr
Net Cash Inflow / Outflow	-324.59 Cr	3.13 Cr	-37.92 Cr	19.46 Cr
Opening Cash & Cash Equivalents	386.46 Cr	61.87 Cr	65 Cr	85.4 Cr
Cash & Cash Equivalent on Amalgamation / Take over / Merger	0	0	58.32 Cr	0
Closing Cash & Cash Equivalent	61.87 Cr	65 Cr	85.4 Cr	104.86 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Equity - Authorised	125 Cr	125 Cr	210 Cr	210 Cr
Equity - Issued	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Equity Paid Up	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Face Value	5	5	5	5
Total Reserves	5752.55 Cr	5868.33 Cr	6028.84 Cr	6686.92 Cr
Securities Premium	4.34 Cr	4.34 Cr	0	0
Capital Reserves	5.56 Cr	5.56 Cr	5.56 Cr	5.56 Cr
Profit & Loss Account Balance	2806.47 Cr	2916.68 Cr	3303.19 Cr	3942.4 Cr
General Reserves	2784.04 Cr	2857.25 Cr	2812.7 Cr	2848.41 Cr
Reserve excluding Revaluation Reserve	5752.55 Cr	5868.33 Cr	6028.84 Cr	6686.92 Cr
Shareholder's Funds	5837.17 Cr	5952.95 Cr	6198.07 Cr	6856.15 Cr
Secured Loans	2963.27 Cr	2123.22 Cr	2496.22 Cr	1603.78 Cr
Non Convertible Debentures	1558.11 Cr	1240.5 Cr	1272.89 Cr	785.28 Cr
Term Loans - Banks	2161.39 Cr	1454.56 Cr	1926.01 Cr	1514.43 Cr
Term Loans - Institutions	400 Cr	400 Cr	333.33 Cr	0
Loans - Others	1.56 Cr	0	0	0
Deferred Tax Assets / Liabilities	-421.66 Cr	-300.09 Cr	-141.73 Cr	100.92 Cr
Deferred Tax Assets	1384.24 Cr	1206.46 Cr	1058.04 Cr	956.04 Cr
Deferred Tax Liability	962.58 Cr	906.37 Cr	916.31 Cr	1056.96 Cr
Other Long Term Liabilities	12.97 Cr	46.28 Cr	75.26 Cr	74.66 Cr
Long Term Provisions	369.62 Cr	368.74 Cr	393.06 Cr	444.69 Cr
Total Non-Current Liabilities	2924.2 Cr	2238.15 Cr	2822.81 Cr	2224.05 Cr
Trade Payables	2066.81 Cr	1674.44 Cr	1678.8 Cr	2089.32 Cr
Sundry Creditors	2066.81 Cr	1674.44 Cr	1678.8 Cr	2089.32 Cr
Other Current Liabilities	1635.36 Cr	1365.1 Cr	1578.41 Cr	1130.15 Cr
Bank Overdraft / Short term credit	54.56 Cr	38.96 Cr	46.25 Cr	17.43 Cr
Advances received from customers	8.73 Cr	10.13 Cr	1.33 Cr	4.5 Cr
Interest Accrued But Not Due	42.73 Cr	34.7 Cr	60.8 Cr	38.17 Cr
Current maturity of Debentures & Bonds	317.86 Cr	467.86 Cr	487.86 Cr	142.86 Cr
Current maturity - Others	26.47 Cr	0	0	0
Short Term Borrowings	704.4 Cr	923.04 Cr	1765.07 Cr	1637.71 Cr
Secured ST Loans repayable on Demands	212.29 Cr	199.97 Cr	997.77 Cr	850 Cr
Short Term Provisions	485.05 Cr	452.51 Cr	425.02 Cr	568.07 Cr
Provision for Tax	53.99 Cr	41.48 Cr	31.31 Cr	167.93 Cr
Provision for post retirement benefits	2.72 Cr	2.9 Cr	3.16 Cr	3.43 Cr
Total Current Liabilities	4891.62 Cr	4415.09 Cr	5447.3 Cr	5425.25 Cr
Total Liabilities	13653 Cr	12606.2 Cr	14468.2 Cr	14505.5 Cr
Gross Block	10511.5 Cr	10728.2 Cr	12811.6 Cr	13484.6 Cr
Less: Accumulated Depreciation	3446.9 Cr	4031.06 Cr	4690.17 Cr	5346.46 Cr
Less: Impairment of Assets	0	274.48 Cr	0	0
Net Block	7064.63 Cr	6422.65 Cr	8121.45 Cr	8138.11 Cr
Capital Work in Progress	745.41 Cr	544.34 Cr	688.24 Cr	280.8 Cr
Non Current Investments	42.09 Cr	42.33 Cr	42.7 Cr	31.8 Cr
Long Term Investment	42.09 Cr	42.33 Cr	42.7 Cr	31.8 Cr
Unquoted	42.09 Cr	42.33 Cr	42.7 Cr	31.8 Cr
Long Term Loans & Advances	81.56 Cr	166.55 Cr	181.04 Cr	349.34 Cr
Other Non Current Assets	52.11 Cr	50.19 Cr	28.41 Cr	14.21 Cr
Total Non-Current Assets	8129.77 Cr	7311.54 Cr	9139 Cr	8893.97 Cr
Currents Investments	139.05 Cr	183.98 Cr	156.09 Cr	141.04 Cr
Quoted	2 Lk	2 Lk	3 Lk	8 Lk
Unquoted	42.09 Cr	42.33 Cr	42.7 Cr	31.8 Cr
Inventories	2681.2 Cr	2462.32 Cr	2229.64 Cr	2279.07 Cr
Raw Materials	985.23 Cr	841.24 Cr	752.49 Cr	643.12 Cr
Work-in Progress	180.32 Cr	177.59 Cr	116.47 Cr	140.95 Cr
Finished Goods	958.23 Cr	1013.08 Cr	859.71 Cr	980.84 Cr
Packing Materials	58.65 Cr	57.62 Cr	57.26 Cr	61.05 Cr
Sundry Debtors	1523.37 Cr	1632.48 Cr	1943.82 Cr	1844.3 Cr
Debtors more than Six months	0	12.22 Cr	24.67 Cr	19.35 Cr
Debtors Others	1541.4 Cr	1627.99 Cr	1930 Cr	1836.16 Cr
Cash and Bank	603.5 Cr	403.41 Cr	571.46 Cr	839.04 Cr
Cash in hand	36 Lk	30 Lk	37 Lk	51 Lk
Balances at Bank	603.14 Cr	403.11 Cr	571.09 Cr	838.53 Cr
Other Current Assets	513.78 Cr	545.33 Cr	246.89 Cr	327.99 Cr
Interest accrued on Investments	14 Lk	5 Lk	1.93 Cr	29 Lk
Prepaid Expenses	54.8 Cr	51.46 Cr	66.69 Cr	58.95 Cr
Short Term Loans and Advances	62.32 Cr	67.13 Cr	165.82 Cr	180.04 Cr
Advances recoverable in cash or in kind	59.24 Cr	63.58 Cr	58.35 Cr	53.39 Cr
Total Current Assets	5523.22 Cr	5294.65 Cr	5313.72 Cr	5611.48 Cr
Net Current Assets (Including Current Investments)	631.6 Cr	879.56 Cr	-133.58 Cr	186.23 Cr
Total Assets	13653 Cr	12606.2 Cr	14468.2 Cr	14505.5 Cr
Contingent Liabilities	122.89 Cr	128.74 Cr	150.83 Cr	157.44 Cr
Total Debt	4874.13 Cr	4018.1 Cr	5297.3 Cr	3937.42 Cr
Book Value	344.91	351.75	0	202.57
Adjusted Book Value	344.91	351.75	183.13	202.57

STANDALONE BALANCE SHEET FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Equity - Authorised	125 Cr	125 Cr	210 Cr	210 Cr
Equity - Issued	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Equity Paid Up	84.62 Cr	84.62 Cr	169.23 Cr	169.23 Cr
Face Value	5	5	5	5
Total Reserves	5945.48 Cr	6260.8 Cr	6286.73 Cr	6659.53 Cr
Securities Premium	4.34 Cr	4.34 Cr	0	0
Profit & Loss Account Balance	2899.91 Cr	3212.92 Cr	3394.21 Cr	3736.39 Cr
General Reserves	2783.95 Cr	2857.16 Cr	2812.62 Cr	2848.33 Cr
Reserve excluding Revaluation Reserve	5945.48 Cr	6260.8 Cr	6286.73 Cr	6659.53 Cr
Shareholder's Funds	6030.1 Cr	6345.42 Cr	6455.96 Cr	6828.76 Cr
Secured Loans	2944.65 Cr	1971.6 Cr	2331.78 Cr	1603.78 Cr
Non Convertible Debentures	1558.11 Cr	1240.5 Cr	1272.89 Cr	785.28 Cr
Term Loans - Banks	2014.38 Cr	1302.94 Cr	1761.57 Cr	1347.68 Cr
Term Loans - Institutions	400 Cr	400 Cr	333.33 Cr	0
Loans - Others	1.56 Cr	0	0	0
Deferred Tax Assets / Liabilities	-28.33 Cr	193.56 Cr	401.3 Cr	655.81 Cr
Deferred Tax Assets	1029.36 Cr	796.86 Cr	612.85 Cr	405.38 Cr
Deferred Tax Liability	1001.03 Cr	990.42 Cr	1014.15 Cr	1061.19 Cr
Other Long Term Liabilities	6.56 Cr	7.79 Cr	29.2 Cr	17.49 Cr
Long Term Provisions	193.93 Cr	210.83 Cr	244.54 Cr	282.15 Cr
Total Non-Current Liabilities	3116.81 Cr	2383.78 Cr	3006.82 Cr	2559.23 Cr
Trade Payables	648.05 Cr	624.21 Cr	610.63 Cr	759.76 Cr
Sundry Creditors	648.05 Cr	624.21 Cr	610.63 Cr	759.76 Cr
Other Current Liabilities	1420.54 Cr	1278.84 Cr	1450.12 Cr	827.9 Cr
Bank Overdraft / Short term credit	54.56 Cr	38.96 Cr	46.25 Cr	17.43 Cr
Advances received from customers	48.18 Cr	49.66 Cr	1.28 Cr	4.5 Cr
Interest Accrued But Not Due	41.45 Cr	34.17 Cr	57.72 Cr	35.3 Cr
Current maturity of Debentures & Bonds	317.86 Cr	467.86 Cr	487.86 Cr	142.86 Cr
Current maturity - Others	16.13 Cr	0	0	0
Short Term Borrowings	410.38 Cr	399.97 Cr	1197.77 Cr	1200 Cr
Secured ST Loans repayable on Demands	212.29 Cr	199.97 Cr	997.77 Cr	850 Cr
Short Term Provisions	106.83 Cr	120.34 Cr	150.63 Cr	200.94 Cr
Provision for Tax	0	0	0	30.2 Cr
Total Current Liabilities	2585.8 Cr	2423.36 Cr	3409.15 Cr	2988.6 Cr
Total Liabilities	11732.7 Cr	11152.6 Cr	12871.9 Cr	12376.6 Cr
Gross Block	9952.74 Cr	10002.3 Cr	12366.9 Cr	12999.8 Cr
Less: Accumulated Depreciation	3211.5 Cr	3751.1 Cr	4395.01 Cr	5013.89 Cr
Net Block	6741.24 Cr	6251.25 Cr	7971.85 Cr	7985.92 Cr
Capital Work in Progress	554.84 Cr	543.54 Cr	674.9 Cr	203.94 Cr
Non Current Investments	174.87 Cr	183.66 Cr	205.12 Cr	322.27 Cr
Long Term Investment	174.87 Cr	183.66 Cr	205.12 Cr	322.27 Cr
Unquoted	208.19 Cr	206.74 Cr	251.84 Cr	368.99 Cr
Long Term Loans & Advances	65.71 Cr	65.3 Cr	68.42 Cr	95.24 Cr
Other Non Current Assets	20.9 Cr	24.8 Cr	1.53 Cr	5.87 Cr
Total Non-Current Assets	7590.83 Cr	7092.51 Cr	8944.85 Cr	8635.53 Cr
Currents Investments	139.05 Cr	183.98 Cr	156.09 Cr	141.04 Cr
Quoted	2 Lk	2 Lk	3 Lk	8 Lk
Unquoted	208.19 Cr	206.74 Cr	251.84 Cr	368.99 Cr
Inventories	1911.74 Cr	1797.11 Cr	1602.23 Cr	1565.59 Cr
Raw Materials	976.32 Cr	839.77 Cr	751.07 Cr	642.03 Cr
Work-in Progress	180.32 Cr	177.59 Cr	116.47 Cr	140.95 Cr
Finished Goods	508.77 Cr	558.62 Cr	462.98 Cr	532.07 Cr
Packing Materials	54.04 Cr	57.62 Cr	57.26 Cr	61.05 Cr
Sundry Debtors	1544.26 Cr	1541.35 Cr	1729.44 Cr	1571.94 Cr
Debtors more than Six months	0	6.22 Cr	22.14 Cr	6.31 Cr
Debtors Others	1553.89 Cr	1539.9 Cr	1712.42 Cr	1572.5 Cr
Cash and Bank	66.42 Cr	69.46 Cr	147.61 Cr	108.76 Cr
Cash in hand	18 Lk	15 Lk	18 Lk	22 Lk
Balances at Bank	66.24 Cr	69.31 Cr	147.43 Cr	108.54 Cr
Other Current Assets	439.82 Cr	426.76 Cr	156.52 Cr	231.24 Cr
Interest accrued on Investments	14 Lk	5 Lk	1.93 Cr	29 Lk
Prepaid Expenses	35.99 Cr	36.31 Cr	51.18 Cr	36.92 Cr
Short Term Loans and Advances	40.59 Cr	41.39 Cr	135.19 Cr	122.49 Cr
Advances recoverable in cash or in kind	37.51 Cr	38.27 Cr	45.22 Cr	37.05 Cr
Total Current Assets	4141.88 Cr	4060.05 Cr	3927.08 Cr	3741.06 Cr
Net Current Assets (Including Current Investments)	1556.08 Cr	1636.69 Cr	517.93 Cr	752.46 Cr
Total Assets	11732.7 Cr	11152.6 Cr	12871.9 Cr	12376.6 Cr
Contingent Liabilities	962.68 Cr	924.71 Cr	1014.11 Cr	1032.87 Cr
Total Debt	4404.14 Cr	3343.41 Cr	4565.56 Cr	3332.96 Cr
Book Value	356.31	0	0	201.76
Adjusted Book Value	356.31	0	190.75	201.76

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	73.97	45.92	36.79	48.94
CEPS(Rs)	112.84	85.05	57.67	72.82
DPS(Rs)	35	48	22	28
Book NAV/Share(Rs)	344.91	351.75	183.13	202.57
Tax Rate(%)	17.98	36.6	32.59	29.58
Margin Ratios
Core EBITDA Margin(%)	16.58	15.98	17.27	20.13
EBIT Margin(%)	12.67	9.74	13.34	16.2
Pre Tax Margin(%)	10.26	8.06	11.3	14.08
PAT Margin (%)	8.41	5.11	7.61	9.92
Cash Profit Margin (%)	12.84	9.46	11.94	14.75
Performance Ratios
ROA(%)	9.2	5.92	9.2	11.43
ROE(%)	23.49	13.18	20.5	25.38
ROCE(%)	17.63	14.35	20.32	24.28
Asset Turnover(x)	1.09	1.16	1.21	1.15
Sales/Fixed Asset(x)	1.43	1.43	1.39	1.27
Working Capital/Sales(x)	23.56	17.29	-122.42	89.7
Efficiency Ratios
Fixed Capital/Sales(x)	0.7	0.7	0.72	0.79
Receivable days	38.92	37.86	39.91	41.38
Inventory Days	59.24	61.71	52.36	49.26
Payable days	129.9	306.08	243.5	279.67
Valuation Parameters
PER(x)	34.35	60.89	41.79	53.15
PCE(x)	22.52	32.88	26.66	35.72
Price/Book(x)	7.37	7.95	8.4	12.84
Yield(%)	1.38	1.72	1.43	1.08
EV/Net Sales(x)	5.91	5.99	5.9	8.5
EV/Core EBITDA(x)	18.6	19.38	19.66	26.61
EV/EBIT(x)	25.09	34.4	26.03	33.68
EV/CE(x)	3.46	4.04	3.92	8.44
M Cap / Sales	5.37	5.56	5.41	8.21
Growth Ratio
Net Sales Growth(%)	0.83	6.29	13.07	11.51
Core EBITDA Growth(%)	10.94	3.58	9.87	18.65
EBIT Growth(%)	15.1	-21.19	47.24	24.08
PAT Growth(%)	22.17	-37.92	60.22	33.02
EPS Growth(%)	22.17	-37.92	-19.88	33.02
Financial Stability Ratios
Total Debt/Equity(x)	0.84	0.68	0.85	0.57
Current Ratio(x)	1.13	1.2	0.98	1.03
Quick Ratio(x)	0.59	0.65	0.57	0.62
Interest Cover(x)	5.26	5.81	6.54	7.65
Total Debt/Mcap(x)	0.11	0.08	0.1	0.04

FINANCIAL RATIOS (STANDALONE) FOR TORRENT PHARMACEUTICALS LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	67.23	58.58	31.06	40.1
CEPS(Rs)	103.27	94.18	50.93	62.58
DPS(Rs)	35	48	22	28
Book NAV/Share(Rs)	356.31	374.94	190.75	201.76
Tax Rate(%)	16.71	32.38	33.33	29.19
Margin Ratios
Core EBITDA Margin(%)	33.54	30.61	31.42	33.18
EBIT Margin(%)	26.03	24.8	23.9	25.49
Pre Tax Margin(%)	20.85	21.36	20.1	22.01
PAT Margin (%)	17.37	14.44	13.4	15.58
Cash Profit Margin (%)	26.68	23.22	21.97	24.32
Performance Ratios
ROA(%)	9.66	8.66	8.75	10.75
ROE(%)	20.41	16.02	16.43	20.43
ROCE(%)	16.34	16.94	18.1	20.96
Asset Turnover(x)	0.56	0.6	0.65	0.69
Sales/Fixed Asset(x)	0.66	0.69	0.7	0.69
Working Capital/Sales(x)	4.21	4.19	15.15	11.57
Efficiency Ratios
Fixed Capital/Sales(x)	1.51	1.45	1.43	1.46
Receivable days	85.05	82.04	76.09	69.19
Inventory Days	95.25	98.61	79.08	66.39
Payable days	53.29	136.79	117.53	131.32
Valuation Parameters
PER(x)	37.8	47.73	49.49	64.87
PCE(x)	24.61	29.69	30.19	41.56
Price/Book(x)	7.13	7.46	8.06	12.89
Yield(%)	1.38	1.72	1.43	1.08
EV/Net Sales(x)	7.34	7.5	7.34	10.7
EV/Core EBITDA(x)	20.45	21.95	22.16	30.62
EV/EBIT(x)	27.76	29.72	30.11	41.12
EV/CE(x)	4.04	4.54	4.39	8.98
M Cap / Sales	6.67	7.02	6.76	10.32
Growth Ratio
Net Sales Growth(%)	4.58	4.52	14.13	10.89
Core EBITDA Growth(%)	7.5	-0.22	10.5	17.02
EBIT Growth(%)	10.23	0.13	10.11	18.4
PAT Growth(%)	21.24	-12.87	6.05	29.07
EPS Growth(%)	21.24	-12.87	-46.97	29.07
Financial Stability Ratios
Total Debt/Equity(x)	0.73	0.53	0.71	0.49
Current Ratio(x)	1.6	1.68	1.15	1.25
Quick Ratio(x)	0.88	0.95	0.69	0.73
Interest Cover(x)	5.02	7.21	6.3	7.32
Total Debt/Mcap(x)	0.1	0.07	0.09	0.04

SHARE HOLDING PATTERN FOR TORRENT PHARMACEUTICALS LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	71.25	71.25	71.25	71.25	71.25	71.25	71.25	71.25	71.25	71.25
FII %	10.80	11.37	12.09	12.04	12.85	13.15	14.08	14.14	14.22	14.46
DII %	0.04	0.05	0.08	0.06	0.09	0.09	0.07	0.07	0.07	0.08
Public %	7.95	7.88	7.80	7.71	7.60	7.60	7.45	7.36	7.26	7.21

PEER COMPARISON FOR TORRENT PHARMACEUTICALS LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR TORRENT PHARMACEUTICALS

Exchange Date	Purpose	Book Closure Dates
BSE 10-Oct-2024	Board Meeting - Quarterly Results	25-Oct-2024
BSE 05-Jul-2024	Board Meeting - Quarterly Results	23-Jul-2024
BSE 24-May-2024	Dividend - Rs.6.0000 per share(120%)Final Dividend
BSE 10-May-2024	Board Meeting - Final Dividend & Audited Results	24-May-2024
BSE 12-Feb-2024	Dividend - Interim Dividend
BSE 12-Jan-2024	Board Meeting - Quarterly Results & Interim Dividend	02-Feb-2024
BSE 09-Oct-2023	Board Meeting - Quarterly Results	23-Oct-2023
BSE 17-Jul-2023	Board Meeting - Quarterly Results	07-Aug-2023
BSE 23-Jun-2023	Dividend - Rs.8.0000 per share(160%)Final Dividend
BSE 16-May-2023	Board Meeting - Final Dividend & Audited Results	30-May-2023
BSE 12-Jan-2023	Board Meeting - Quarterly Results & Interim Dividend	25-Jan-2023
BSE 12-Jan-2023	Dividend - Interim Dividend
BSE 04-Oct-2022	Board Meeting - Quarterly Results	21-Oct-2022
BSE 11-Jul-2022	Board Meeting - Quarterly Results	29-Jul-2022
BSE 03-Jun-2022	Dividend - Rs.15.0000 per share(300%)Special Dividend
BSE 25-May-2022	Bonus issue - Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Monday, 6th June, 2022 as the Record Date for taking record of the Members of theCompany entitled for the purpose of payment of final dividend for the year 2021-22, if declared by the Company.
BSE 23-May-2022	Bonus issue - Final Dividend & Bonus issue & Audited Results	25-May-2022
BSE 06-May-2022	Board Meeting - Final Dividend & Audited Results	25-May-2022
BSE 02-Feb-2022	Dividend - Interim Dividend
BSE 10-Jan-2022	Board Meeting - Quarterly Results & Interim Dividend	25-Jan-2022
BSE 11-Oct-2021	Board Meeting - Quarterly Results	26-Oct-2021

CORPORATE ANNOUNCEMENTS FOR TORRENT PHARMACEUTICALS

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earning Call Transcript
BSE 30-Oct-2024	General FILE	Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Torrent Investments Pvt Ltd
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter and half year ended 30th September 2024.
BSE 25-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation on Financial Results Q2 FY 2024-25.
BSE 25-Oct-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Dated 25-10-2024 Outcome of Board Meeting Dated 25-10-2024
BSE 25-Oct-2024	Outcome FILE	Results Q2 FY 2024-25 Results Q2 FY 2024-25.
BSE 24-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Credit Rating Intimation of Credit Rating
BSE 24-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificates
BSE 21-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificates
BSE 18-Oct-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 15-Oct-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 14-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Post Quarterly Financial Result Conference call with investors / analyst
BSE 10-Oct-2024	Intimation FILE	Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on 30-Sep-24.
BSE 27-Sep-2024	Intimation FILE	Closure of Trading Window Intimation of Closure of Trading Window
BSE 26-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Acquisition Intimation for Incorporation of Wholly Owned Subsidiary (WOS)
BSE 26-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release Attached.
BSE 25-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of issue of duplicate share certificates
BSE 24-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Investors Meets under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 24-Sep-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificates
BSE 20-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Issue of Securities Intimation regarding Issue of Commercial Papers
BSE 20-Sep-2024	General Announcements FILE	Announcement Under Regulation 30 Of LODR. PFA
BSE 02-Sep-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under regulation 30 of SEBI Listing Regulations
BSE 30-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificate
BSE 30-Aug-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Issue of Duplicate Share Certificates
BSE 30-Aug-2024	General Announcements FILE	Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 29-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 28-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 27-Aug-2024	General Announcements FILE	Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Disclosure under regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
BSE 23-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Credit Rating Intimation of Credit Rating
BSE 14-Aug-2024	General Announcements FILE	Clarification / Information On News Item Clarification / Information on news item

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Insider trading details found

BULK BLOCK DEALS FOR TORRENT PHARMACEUTICALS LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 30-Oct-2024	Sell BULK	4,972,020 @ 3103.07	TORRENT INVESTMENTS PRIVATE LIMITED
BSE 30-Oct-2024	Sell BULK	4,972,020 @ 3104.40	TORRENT INVESTMENTS PRIVATE LIMITED
BSE 25-Jan-2024	Sell BLOCK	55,561 @ 2507.05	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Sell BLOCK	474,629 @ 2507.05	BNP PARIBAS ARBITRAGE
BSE 25-Jan-2024	Buy BLOCK	3,883 @ 2507.05	MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND
BSE 25-Jan-2024	Buy BLOCK	4,356 @ 2507.05	MARSHALL WACE INVESTMENT STRATEGIESGTOPS FUND
BSE 25-Jan-2024	Buy BLOCK	47,322 @ 2507.05	MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND
BSE 25-Jan-2024	Buy BLOCK	474,629 @ 2507.05	SOCIETE GENERALE
BSE 25-Oct-2022	Sell BLOCK	86,000 @ 1567.30	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 25-Oct-2022	Buy BLOCK	86,000 @ 1567.30	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 17-Oct-2022	Sell BLOCK	135,148 @ 1595.05	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 17-Oct-2022	Buy BLOCK	135,148 @ 1595.05	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 11-Oct-2022	Sell BLOCK	132,154 @ 1593.65	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 11-Oct-2022	Buy BLOCK	132,154 @ 1593.65	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 19-Sep-2022	Sell BLOCK	89,889 @ 1478.70	ISHARES CORE EMERGING MARKETS MAURITIUS CO
BSE 19-Sep-2022	Buy BLOCK	89,889 @ 1478.70	ISHARES CORE MSCI EMERGING MARKETS ETF
BSE 01-Aug-2022	Sell BLOCK	120,521 @ 1528.80	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 01-Aug-2022	Buy BLOCK	120,521 @ 1528.80	ISHARES MSCI INDIA ETF
BSE 18-Jul-2022	Sell BLOCK	120,878 @ 1518.00	ISHARES INDIA INDEX MAURITIUS COMPANY
BSE 18-Jul-2022	Buy BLOCK	120,878 @ 1518.00	ISHARES MSCI INDIA ETF
BSE 04-May-2022	Buy BLOCK	74,817 @ 2792.50	ISHARES CORE MSCI TOTAL INTERNATIONAL STOCK ETF
BSE 04-May-2022	Sell BLOCK	74,817 @ 2792.50	ISHARES CORE TOTAL INTERNATIONAL STOCK MAURITIUS CO
BSE 20-Oct-2021	Sell BLOCK	47,426 @ 3072.95	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 20-Oct-2021	Buy BLOCK	47,426 @ 3072.95	ISHARES MSCI EMERGING MARKETS ETF
BSE 11-Oct-2021	Sell BLOCK	47,426 @ 3075.30	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 11-Oct-2021	Buy BLOCK	47,426 @ 3075.30	ISHARES MSCI EMERGING MARKETS ETF
BSE 24-Sep-2021	Buy BLOCK	377,285 @ 3102.20	GOLDMAN SACHS FDS GOLDMAN SACHS INDIA EQ PORTFOLIO
BSE 24-Sep-2021	Sell BLOCK	377,285 @ 3102.20	GOLDMAN SACHS INDIA FUND LIMITED
BSE 23-Sep-2021	Sell BLOCK	48,273 @ 3085.50	ISHARES EMERGING MARKETS INDEX MAURITIUS CO
BSE 23-Sep-2021	Buy BLOCK	48,273 @ 3085.50	ISHARES MSCI EMERGING MARKETS ETF

DIVIDEND BY TORRENT PHARMACEUTICALS LIMITED

Ex Dividend Date	Dividend Type	Dividend
31-Jan-2025	INTERIM DIVIDEND	26
21-Jun-2024	DIVIDEND	6
12-Feb-2024	INTERIM DIVIDEND	22
23-Jun-2023	DIVIDEND	8
03-Feb-2023	INTERIM DIVIDEND	14
03-Jun-2022	DIVIDEND	8
03-Jun-2022	SPECIAL DIVIDEND	15
03-Jun-2022	DIVIDEND	15
02-Feb-2022	INTERIM DIVIDEND	25
17-Jun-2021	DIVIDEND	15
15-Feb-2021	INTERIM DIVIDEND	20